REG-4basebio Plc: Director Dealing

4BasebioAnnouncement

30/09/2025 16:30

30 September 2025

   
     


4basebio PLC

("4basebio" or the "Company")

Director Dealing

Cambridge, UK, 30 September 2025 – 4basebio PLC (AIM: 4BB), an
innovation-led provider of novel synthetic DNA products and a non-viral,
thermostable nucleic acid delivery platform, announces that it was informed by
Dr. Heikki Lanckriet, CEO of the Company, that on 29 September 2025 he made
the following purchase in ordinary shares in the capital of the Company
through the market.

Further details are set out in the Notification of Dealing Form below.


 Director / PCA    Number of Ordinary Shares Acquired  Purchase Price (Aggregated) (p)  Shareholding Following Acquisition  Shareholding Following Acquisition as a Percentage of Issued Share Capital  
 Heikki Lanckriet  2,000                               749                              1,119,688                           7.21%                                                                       

The 2,000 additional shares purchased represent approximately 0.01 per cent.
of the Company's issued share capital. The issued share capital of the Company
comprises 15,538,518 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC Dr. Heikki Lanckriet, CEO                                                               +44 (0) 1223 967 943  
 Nominated Adviser        Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes         +44 (0) 20 7213 0880  
 Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes                                     +44 (0) 20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks                              +44 (0) 20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 1           Details of the persons discharging managerial responsibilities / person closely associated                                                                                                            
 a)          Name                                                                                               Heikki Lanckriet                                                                                   
 2           Reason for the notification                                                                                                                                                                           
 a)          Position/Status                                                                                    Chief Executive Officer                                                                            
 b)          Initial notification/ Amendment                                                                    Initial notification                                                                               
 3           Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         
 a)          Name                                                                                               4basebio plc                                                                                       
 b)          LEI                                                                                                213800E2DX9EAIUNCB30                                                                               
 4           Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     
 a)          Description of the financialinstrument, type ofinstrumentIdentification code                       Ordinary Shares                                                                                    
                                                                                                                			                                                                                                
                                                                                                                			ISIN: GB00BMCLYF79                                                                              
 b)          Nature of the transaction                                                                          Acquisition of ordinary shares                                                                     
 c)          Price(s) and volume(s)                                                                                                                                                                                
 Date        Price(s)                                                                                           Volume(s)                                                                                          
 29/09/2025  750p                                                                                               1,000                                                                                              
 29/09/2025  748p                                                                                               1,000                                                                                              
 d)          Aggregated information-      Aggregated volume-      Aggregated Price                              2,000749p                                                                                          
 e)          Date of transaction                                                                                29 September 2025                                                                                  
 f)          Place of transaction                                                                               London Stock Exchange                                                                              



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved